Literature DB >> 18987048

Commentary: hormone receptor testing in breast cancer: a distress signal from Canada.

D Craig Allred1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18987048     DOI： 10.1634/theoncologist.2008-0184

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  24 in total

Review 1.  Cancer biomarkers.

Authors:  N Lynn Henry; Daniel F Hayes
Journal:  Mol Oncol       Date:  2012-02-06       Impact factor: 6.603

2.  Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis.

Authors:  Lajos Pusztai; Giuseppe Viale; Catherine M Kelly; Clifford A Hudis
Journal:  Oncologist       Date:  2010-11-01

3.  Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.

Authors:  Allison W Welsh; Christopher B Moeder; Sudha Kumar; Peter Gershkovich; Elaine T Alarid; Malini Harigopal; Bruce G Haffty; David L Rimm
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

4.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Authors:  D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

5.  Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5.

Authors:  Allison W Welsh; Malini Harigopal; Hallie Wimberly; Manju Prasad; David L Rimm
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-03

6.  Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.

Authors:  Paul W Sperduto; Shane Mesko; Jing Li; Daniel Cagney; Ayal Aizer; Nancy U Lin; Eric Nesbit; Tim J Kruser; Jason Chan; Steve Braunstein; Jessica Lee; John P Kirkpatrick; Will Breen; Paul D Brown; Diana Shi; Helen A Shih; Hany Soliman; Arjun Sahgal; Ryan Shanley; William Sperduto; Emil Lou; Ashlyn Everett; Drexell Hunter Boggs; Laura Masucci; David Roberge; Jill Remick; Kristin Plichta; John M Buatti; Supriya Jain; Laurie E Gaspar; Cheng-Chia Wu; Tony J C Wang; John Bryant; Michael Chuong; James Yu; Veronica Chiang; Toshimichi Nakano; Hidefumi Aoyama; Minesh P Mehta
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

7.  Discordance between original and central laboratories in ER and HER2 results in a diverse, population-based sample.

Authors:  Jennifer J Griggs; Ann S Hamilton; Kendra L Schwartz; Weiqiang Zhao; Paul H Abrahamse; Dafydd G Thomas; Julie M Jorns; Rachel Jewell; Maria E Sibug Saber; Reina Haque; Steven J Katz
Journal:  Breast Cancer Res Treat       Date:  2016-11-29       Impact factor: 4.872

8.  Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.

Authors:  Qiyuan Li; Aron C Eklund; Nicolai Juul; Benjamin Haibe-Kains; Christopher T Workman; Andrea L Richardson; Zoltan Szallasi; Charles Swanton
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

9.  A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-04-29       Impact factor: 7.842

10.  Reliability of receptor assessment on core needle biopsy in breast cancer patients.

Authors:  S C Seferina; M Nap; F van den Berkmortel; J Wals; A C Voogd; V C G Tjan-Heijnen
Journal:  Tumour Biol       Date:  2012-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.